drugset / Trial / NCT04043845
ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies
NaSingle-groupOpen-labelTreatment
Summary
This research is studying the safety of combining ibrutinib with the study drug LY3214996 for chronic lymphocytic leukemia (CLL), Waldenstrom's macroglobulinemia (WM), mantle cell lymphoma (MCL), or marginal zone lymphoma (MZL).
Timeline
- Start
- 2020-02-03
- Primary completion
- 2020-02-03
- Completion
- 2020-02-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TEMUTERKIB | Small molecule | — | Oral |
| Background | Ibrutinib | Small molecule | — | Oral |